Lord, Abbett & Co’s Revance Therapeutics, Inc. RVNC Stock Holding History

Lord, Abbett & Co’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,248,586	Closed	-$31.6M	–	595
2023 Q2	$31.6M	Buy	1,248,586 +1,016,810	+439%	+$31.7M	0.11%	256
2023 Q1	$7.46M	Buy	+231,776	New	+$7.23M	0.03%	435
2016 Q2	–	Sell	-94,700	Closed	-$1.65M	–	935
2016 Q1	$1.65M	Sell	94,700 -515,068	-84%	-$10.5M	0.01%	845
2015 Q4	$20.8M	Buy	609,768 +410,224	+206%	+$14.2M	0.06%	417
2015 Q3	$5.94M	Sell	199,544 -1,822	-0.9%	-$55.3K	0.02%	699
2015 Q2	$6.44M	Buy	+201,366	New	+$5.18M	0.02%	729
2014 Q4	–	Sell	-278,607	Closed	-$5.38M	–	995
2014 Q3	$5.38M	Buy	278,607 +77,924	+39%	+$2.03M	0.01%	734
2014 Q2	$6.82M	Buy	200,683 +76,783	+62%	+$2.41M	0.02%	735
2014 Q1	$3.9M	Buy	+123,900	New	+$3.87M	0.01%	832

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lord, Abbett & Co's RVNC Position: Q3 2023 in Review

Lord, Abbett & Co sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 1,248,586 shares — an estimated $31.6M sold.

Lord, Abbett & Co first reported a position in RVNC in Q1 2014 and held it in 9 quarters. The position peaked at $31.6M in Q2 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

Lord, Abbett & Co reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
Lord, Abbett & Co sold 1,248,586 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $31.6M.
Lord, Abbett & Co first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 9 quarters.
Lord, Abbett & Co's Revance Therapeutics, Inc. position peaked at $31.6M in Q2 2023.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Lord, Abbett & Co's 13F filing for Q3 2023, filed 13 Nov 2023.